Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Remains a Sell on Pfizer (PFE)

Tipranks - Tipranks - Wed Apr 22, 4:10AM CDT

Barclays analyst Emily Field maintained a Sell rating on Pfizer today and set a price target of $25.00.

Claim 30% Off TipRanks

According to TipRanks, Field is a 3-star analyst with an average return of 1.4% and a 42.94% success rate. Field covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Cytokinetics.

In addition to Barclays, Pfizer also received a Sell from RBC Capital’s Trung Huynh in a report issued yesterday. However, on April 16, Goldman Sachs upgraded Pfizer (NYSE: PFE) to a Buy.

See today’s best-performing stocks on TipRanks >>

Based on Pfizer’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.56 billion and a GAAP net loss of $1.65 billion. In comparison, last year the company earned a revenue of $17.76 billion and had a net profit of $403 million

Read More on PFE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).